SE0104330D0 - Therapeutic agents - Google Patents
Therapeutic agentsInfo
- Publication number
- SE0104330D0 SE0104330D0 SE0104330A SE0104330A SE0104330D0 SE 0104330 D0 SE0104330 D0 SE 0104330D0 SE 0104330 A SE0104330 A SE 0104330A SE 0104330 A SE0104330 A SE 0104330A SE 0104330 D0 SE0104330 D0 SE 0104330D0
- Authority
- SE
- Sweden
- Prior art keywords
- sub
- sup
- group
- optionally substituted
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (25)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0104330A SE0104330D0 (sv) | 2001-12-19 | 2001-12-19 | Therapeutic agents |
PCT/GB2002/005742 WO2003051851A1 (en) | 2001-12-19 | 2002-12-18 | 5, 6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists |
PL02369731A PL369731A1 (en) | 2001-12-19 | 2002-12-18 | 5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists |
KR10-2004-7009589A KR20040068286A (ko) | 2001-12-19 | 2002-12-18 | Cb1 길항물질로서의 5,6-디아릴-피라진-2-아미드 유도체 |
DE60218340T DE60218340T2 (de) | 2001-12-19 | 2002-12-18 | 5,6-diaryl-pyrazineamidderivate als cb1 antagonisten |
MXPA04005990A MXPA04005990A (es) | 2001-12-19 | 2002-12-18 | Derivados de 5,6-diaril-pirazina-2-amida como antagonistas de cb1. |
ES02788143T ES2280599T3 (es) | 2001-12-19 | 2002-12-18 | Derivados de 5,6-diaril-pirazin-2-amida como antagonistas de cb1. |
JP2003552736A JP2005517655A (ja) | 2001-12-19 | 2002-12-18 | Cb1アンタゴニストとしての5,6−ジアリール−ピラジン−2−アミド誘導体 |
NZ533275A NZ533275A (en) | 2001-12-19 | 2002-12-18 | 5, 6-Diaryl-pyrazine-2-amide derivatives as CB1 antagonists |
CNA028281535A CN1620438A (zh) | 2001-12-19 | 2002-12-18 | 用作cbi拮抗剂的5,6-二芳基-吡嗪-2-酰胺衍生物 |
AT02788143T ATE354570T1 (de) | 2001-12-19 | 2002-12-18 | 5,6-diaryl-pyrazineamidderivate als cb1 antagonisten |
EP02788143A EP1458690B1 (de) | 2001-12-19 | 2002-12-18 | 5,6-diaryl-pyrazineamidderivate als cb1 antagonisten |
BR0214989-3A BR0214989A (pt) | 2001-12-19 | 2002-12-18 | Composto, formulação farmacêutica, uso de um composto, método de tratamento de doenças, e, processo para a preparação de um composto |
HU0402026A HUP0402026A3 (en) | 2001-12-19 | 2002-12-18 | 5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists, process for their preparation and pharmaceutical compositions containing them |
AU2002352425A AU2002352425A1 (en) | 2001-12-19 | 2002-12-18 | 5,6-diaryl-pyrazine-2-amide derivatives as CB1 antagonists |
CA002469786A CA2469786A1 (en) | 2001-12-19 | 2002-12-18 | 5, 6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists |
US10/499,054 US7342019B2 (en) | 2001-12-19 | 2002-12-18 | 5, 6-diaryl-pyrazine-2-amide derivatives as CB1 antagonists |
IL16237702A IL162377A0 (en) | 2001-12-19 | 2002-12-18 | 5,6-Diaryl-pyrazine-2-amide derivatives as cb1 antagonists |
RU2004116916/04A RU2004116916A (ru) | 2001-12-19 | 2002-12-18 | Производные 5,6-биарил-пиразин-2-амида в качестве антагонистов cb1 |
TW091136671A TW200410694A (en) | 2001-12-19 | 2002-12-19 | Therapeutic agents |
ARP020105001A AR038044A1 (es) | 2001-12-19 | 2002-12-19 | Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso. |
IS7314A IS7314A (is) | 2001-12-19 | 2004-06-16 | 5,6-díarýl-pýrasín-2-amíðafleiður sem cb1 mótlyf |
ZA200404805A ZA200404805B (en) | 2001-12-19 | 2004-06-17 | 5,6-diaryl-pyrazine-2-amide derivatives as CB1 antagonists. |
CO04065292A CO5590917A2 (es) | 2001-12-19 | 2004-07-09 | Derivados de 5,6-diaril-pirazina-2-amida como antagonistas cb1 |
NO20043022A NO20043022L (no) | 2001-12-19 | 2004-07-15 | 5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0104330A SE0104330D0 (sv) | 2001-12-19 | 2001-12-19 | Therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
SE0104330D0 true SE0104330D0 (sv) | 2001-12-19 |
Family
ID=20286429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE0104330A SE0104330D0 (sv) | 2001-12-19 | 2001-12-19 | Therapeutic agents |
Country Status (25)
Country | Link |
---|---|
US (1) | US7342019B2 (de) |
EP (1) | EP1458690B1 (de) |
JP (1) | JP2005517655A (de) |
KR (1) | KR20040068286A (de) |
CN (1) | CN1620438A (de) |
AR (1) | AR038044A1 (de) |
AT (1) | ATE354570T1 (de) |
AU (1) | AU2002352425A1 (de) |
BR (1) | BR0214989A (de) |
CA (1) | CA2469786A1 (de) |
CO (1) | CO5590917A2 (de) |
DE (1) | DE60218340T2 (de) |
ES (1) | ES2280599T3 (de) |
HU (1) | HUP0402026A3 (de) |
IL (1) | IL162377A0 (de) |
IS (1) | IS7314A (de) |
MX (1) | MXPA04005990A (de) |
NO (1) | NO20043022L (de) |
NZ (1) | NZ533275A (de) |
PL (1) | PL369731A1 (de) |
RU (1) | RU2004116916A (de) |
SE (1) | SE0104330D0 (de) |
TW (1) | TW200410694A (de) |
WO (1) | WO2003051851A1 (de) |
ZA (1) | ZA200404805B (de) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7704995B2 (en) | 2002-05-03 | 2010-04-27 | Exelixis, Inc. | Protein kinase modulators and methods of use |
GB0216700D0 (en) | 2002-07-18 | 2002-08-28 | Astrazeneca Ab | Process |
EP1546115A4 (de) | 2002-09-27 | 2010-08-04 | Merck Sharp & Dohme | Substituierte pyrimidine |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
GB0230088D0 (en) * | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
GB0302673D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
GB0302671D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
GB0314057D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
US20060135523A1 (en) * | 2003-06-18 | 2006-06-22 | Astrazeneca Ab | 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator |
GB0314049D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
GB0314261D0 (en) * | 2003-06-19 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
WO2005007111A2 (en) | 2003-07-11 | 2005-01-27 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
US7326706B2 (en) * | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
CA2537535A1 (en) * | 2003-09-02 | 2005-03-10 | Solvay Pharmaceuticals Gmbh | Novel medical use of selective cb1-receptor antagonists |
US7320805B2 (en) * | 2003-10-01 | 2008-01-22 | Institut National De La Sante Et De La Recherche Medicale | CB2 receptors blocks accumulation of human hepatic myofibroblasts: a novel artifibrogenic pathway in the liver |
WO2005037199A2 (en) | 2003-10-10 | 2005-04-28 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
CN1867332A (zh) * | 2003-10-24 | 2006-11-22 | 索尔瓦药物有限公司 | 包含选择性cb1-拮抗剂和脂肪酶抑制剂的肥胖症的联合治疗 |
AR046132A1 (es) * | 2003-10-24 | 2005-11-23 | Solvay Pharm Gmbh | Composicin farmaceutica que contiene al menos un compuesto con actividad de receptor de cb1, o un profarmaco , tautomero o sal del mismo, como componente activo adecuado para el tratamiento y/o profilaxis de enfermedades relacionadas con el receptor cb1 en pacientes juveniles y/o para el tratamiento |
GB0327331D0 (en) * | 2003-11-25 | 2003-12-31 | Astrazeneca Ab | Therapeutic agents |
WO2005097127A2 (en) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Method of treating men with metabolic and anthropometric disorders |
TW200602314A (en) | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
JP2008517976A (ja) | 2004-10-25 | 2008-05-29 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb1カンナビノイド受容体拮抗薬及びカリウムチャンネルオープナーから成る、真性糖尿病1型、肥満及び関連症状の治療用の医薬組成物 |
MX2007012213A (es) | 2005-04-06 | 2007-12-10 | Hoffmann La Roche | Derivados de piridin-3-carboxamida como agonistas inversos de canabinoides. |
JP2008536950A (ja) * | 2005-04-18 | 2008-09-11 | ニューロジェン・コーポレーション | 置換ヘテロアリールのcb1拮抗薬 |
BRPI0613505A2 (pt) | 2005-06-30 | 2011-01-11 | Prosidion Ltd | agonistas de gpcr |
US7629346B2 (en) | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
AU2007304365A1 (en) * | 2006-10-04 | 2008-04-10 | F. Hoffmann-La Roche Ag | 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents |
DK2114933T3 (da) | 2007-01-04 | 2012-01-02 | Prosidion Ltd | Piperidin-GPCR-agonister |
WO2008081208A1 (en) | 2007-01-04 | 2008-07-10 | Prosidion Limited | Piperidine gpcr agonists |
AR064736A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr |
GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
AR064735A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr y composicion farmaceutica en base al compuesto |
GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
WO2010079241A1 (es) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas |
US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
US9403808B2 (en) * | 2011-10-28 | 2016-08-02 | Hoffmann-La Roche Inc. | Pyrazine derivatives |
CA3190418A1 (en) | 2020-08-06 | 2022-02-10 | Chdi Foundation, Inc. | Heterobiaryl compounds and imaging agents for imaging huntingtin protein |
WO2024159286A1 (pt) * | 2023-01-30 | 2024-08-08 | Eurofarma Laboratórios S.A. | Compostos fenólicos bloqueadores de nav 1.7 e/ou nav 1.8, seus processos de obtenção, composições, usos, métodos de tratamento destes e kits |
WO2024159284A1 (pt) * | 2023-01-30 | 2024-08-08 | Eurofarma Laboratórios S.A. | Hidrazidas bloqueadoras de nav 1.7 e/ou nav 1.8, seus processos de obtenção, composições, usos, métodos de tratamento destes e kits |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH458361A (de) | 1965-01-15 | 1968-06-30 | Eprova Ag | Verfahren zur Herstellung von Pyrazincarbonsäuren |
JPS5322529A (en) * | 1976-08-13 | 1978-03-02 | Nippon Soda Co Ltd | Dihydropyrazine derivative and its preparation |
WO1989004308A1 (en) | 1987-11-12 | 1989-05-18 | Terumo Kabushiki Kaisha | Pyrazine derivatives and medicinal preparation containing same |
JPH06501926A (ja) * | 1990-08-06 | 1994-03-03 | 藤沢薬品工業株式会社 | 複素環式化合物 |
FR2713225B1 (fr) * | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
-
2001
- 2001-12-19 SE SE0104330A patent/SE0104330D0/xx unknown
-
2002
- 2002-12-18 PL PL02369731A patent/PL369731A1/xx not_active Application Discontinuation
- 2002-12-18 EP EP02788143A patent/EP1458690B1/de not_active Expired - Lifetime
- 2002-12-18 KR KR10-2004-7009589A patent/KR20040068286A/ko not_active Application Discontinuation
- 2002-12-18 WO PCT/GB2002/005742 patent/WO2003051851A1/en active IP Right Grant
- 2002-12-18 MX MXPA04005990A patent/MXPA04005990A/es unknown
- 2002-12-18 NZ NZ533275A patent/NZ533275A/en unknown
- 2002-12-18 AT AT02788143T patent/ATE354570T1/de not_active IP Right Cessation
- 2002-12-18 JP JP2003552736A patent/JP2005517655A/ja active Pending
- 2002-12-18 IL IL16237702A patent/IL162377A0/xx unknown
- 2002-12-18 CA CA002469786A patent/CA2469786A1/en not_active Abandoned
- 2002-12-18 US US10/499,054 patent/US7342019B2/en not_active Expired - Fee Related
- 2002-12-18 DE DE60218340T patent/DE60218340T2/de not_active Expired - Fee Related
- 2002-12-18 RU RU2004116916/04A patent/RU2004116916A/ru not_active Application Discontinuation
- 2002-12-18 HU HU0402026A patent/HUP0402026A3/hu unknown
- 2002-12-18 ES ES02788143T patent/ES2280599T3/es not_active Expired - Lifetime
- 2002-12-18 CN CNA028281535A patent/CN1620438A/zh active Pending
- 2002-12-18 AU AU2002352425A patent/AU2002352425A1/en not_active Abandoned
- 2002-12-18 BR BR0214989-3A patent/BR0214989A/pt not_active IP Right Cessation
- 2002-12-19 TW TW091136671A patent/TW200410694A/zh unknown
- 2002-12-19 AR ARP020105001A patent/AR038044A1/es not_active Application Discontinuation
-
2004
- 2004-06-16 IS IS7314A patent/IS7314A/is unknown
- 2004-06-17 ZA ZA200404805A patent/ZA200404805B/en unknown
- 2004-07-09 CO CO04065292A patent/CO5590917A2/es not_active Application Discontinuation
- 2004-07-15 NO NO20043022A patent/NO20043022L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MXPA04005990A (es) | 2004-09-27 |
NZ533275A (en) | 2006-02-24 |
TW200410694A (en) | 2004-07-01 |
ATE354570T1 (de) | 2007-03-15 |
ZA200404805B (en) | 2005-08-15 |
JP2005517655A (ja) | 2005-06-16 |
IS7314A (is) | 2004-06-16 |
US20050032808A1 (en) | 2005-02-10 |
CO5590917A2 (es) | 2005-12-30 |
DE60218340T2 (de) | 2007-11-29 |
BR0214989A (pt) | 2004-12-14 |
RU2004116916A (ru) | 2005-11-10 |
CA2469786A1 (en) | 2003-06-26 |
PL369731A1 (en) | 2005-05-02 |
WO2003051851A1 (en) | 2003-06-26 |
ES2280599T3 (es) | 2007-09-16 |
AU2002352425A1 (en) | 2003-06-30 |
NO20043022L (no) | 2004-07-15 |
EP1458690B1 (de) | 2007-02-21 |
DE60218340D1 (de) | 2007-04-05 |
HUP0402026A2 (hu) | 2005-02-28 |
CN1620438A (zh) | 2005-05-25 |
EP1458690A1 (de) | 2004-09-22 |
US7342019B2 (en) | 2008-03-11 |
IL162377A0 (en) | 2005-11-20 |
KR20040068286A (ko) | 2004-07-30 |
HUP0402026A3 (en) | 2005-08-29 |
AR038044A1 (es) | 2004-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE0104330D0 (sv) | Therapeutic agents | |
TW200503692A (en) | Therapeutic agents | |
TW200507839A (en) | Therapeutic agents | |
HUP0402150A2 (hu) | A CB1 jelzésű kannabinoid receptorra nézve agonista, parciális agonista vagy antagonista hatású 1H-imidazol-származékok, eljárás az előállításukra, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk gyógyszerkészítmények előállítására | |
EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
WO2004020431A3 (en) | Novel benzoimidazole derivatives useful as antiproliferative agents | |
NO20055421L (no) | Kinolinderivater som fosfodiestrase-inhibitorer | |
AU7517400A (en) | N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent | |
WO2002089782A3 (en) | Dioxanes and uses thereof | |
PT842923E (pt) | Derivados do pirrolo e composicoes medicinais | |
AU8799201A (en) | Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases | |
EA200501703A1 (ru) | Применение производных азетидинкарбоксамида в терапии | |
PL353646A1 (en) | Aminobenzophenones as inhibitors of il-1beta and tnf-alpha | |
SI1210320T1 (en) | Aminobenzophenones as inhibitors of il-1beta and tnf-alpha | |
IL148875A0 (en) | Sulfonyl hydrazide derivatives, their preparation and pharmaceutical compositions containing them | |
AP9901578A0 (en) | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents. | |
CA2345069A1 (en) | 2-phenylpyran-4-one derivatives | |
DE69512816D1 (de) | Oxopyridylchinoxalin Derivate | |
DE69828197D1 (de) | Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut | |
NO996284L (no) | Nye imidazolinforbindelser, fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger inneholdende dem | |
DE60226971D1 (de) | Corticotropinfreisetzungsfaktor antagonisten | |
HK1096670A1 (en) | Pyrrolo-pyrazine derivatives useful as cb1-modulators | |
ATE409698T1 (de) | 1,2,4-triazolderivat, verfahren zu dessen herstellung, und dieses enthaltende pharmazeutische zusammensetzung | |
AP2002002707A0 (en) | 4, 5-Dihydro-Thiazo-2-Ylamine Derivatives and their Use as NO-Synthase Inhibitors. |